21.03.2013 - EPFL scientists have developed a tiny, portable personal blood testing implant that sends diagnostic data through mobile phone network.
A tiny subcutaneously implanted blood testing chip can analyse several diagnostic blood parameters and then transmit the results directly to a doctor's computer. The device, developed by researchers at Swiss EPFL in Lausanne is good news for patients with chronic illness such as diabetes or those undergoing chemotherapy, whose blood needs to be monitored permanently. The implant offers an alternative to non-invasive sensors under development, which measure through the skin.
Each of the 5 sensor's surfaces can be covered with an enzyme that allows to detect a blood metabolite or with an antibody that captures specific protein markers. The few cubic centimetre-large chip's sensors can trace blood glucose, proteins, ATP or organic acids such as lactate simultaneously, Giovanni de Micheli and Sandro Carrara announced at DATE 13, Europe's largest electronics conference.
Potentially, we could detect just about anything," explains De Micheli. "But the enzymes have a limited lifespan." The enzymes currently being tested are good for about a month and a half; that's already long enough for many applications.." After the measurement, the implant emits radio waves over a safe frequency. The patch collects the data and transmits them via Bluetooth to a mobile phone, which then sends them to the doctor over the cellular network. The implant could be particularly useful in chemotherapy applications.
Currently, oncologists use occasional blood tests to evaluate their patients' tolerance to a particular treatment dosage. Additionally, in patients with chronic disorders, the implants could send alerts even before symptoms emerge, and anticipate the need for medication. The researchers hope the system will be commercially available within 4 years.
29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.
24.08.2014 Germany's Morphosys is licensing a preclinical bi-specific antibody for the treatment of prostate cancer from Emergent Biosolutions. The US developer will rake in up to €138m for the commercialisation rights to the compound.
20.08.2014 Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.